BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-than-expected loss as development and launch spending increased.

That split matters for investors. Attruby is scaling quickly while BridgeBio funds several late-stage programs and potential launches. The question for the rest of 2026 is whether first-line ATTR-CM share gains can keep revenue momentum moving.

BBIO’s Q2 Sales Beat Came From Attruby

Second-quarter revenues reached $243.7 million, above the Zacks Consensus Estimate of $222.6 million. Attruby generated $222.4 million in U.S. product sales, more than tripling from $71.5 million a year earlier and accounting for most of the quarter's top line.

Royalty revenues rose to $15.4 million from $1.6 million, mainly on Beyonttra sales in the European Union and Japan. License and services revenues fell more than 84% to $5.8 million because the year-earlier period included a $30 million regulatory milestone.

BridgeBio’s Loss Shows the Cost of Expansion

BridgeBio lost 78 cents per share, wider than the Zacks Consensus Estimate of a 64-cent loss, though the result improved from a 95-cent loss a year earlier. Revenue growth has not yet translated into profitability.

Research and development expenses increased 34% to $149.4 million as BridgeBio invested in late-stage programs. Selling, general and administrative expenses climbed 44% to $186.3 million as the company supported Attruby commercialization and pre-commercial work for upcoming launches.

BridgeBio Pharma, Inc. Price and EPS Surprise

 

BridgeBio Pharma, Inc. price-eps-surprise | BridgeBio Pharma, Inc. Quote

BBIO’s First-Line Share Gains Matter for 2026

Management sees treatment-naive patients as Attruby's key long-term growth source. The pool of patients switching from Pfizer's Vyndaqel/Vyndamax has begun to normalize after elevated activity in prior quarters. BridgeBio estimated that Attruby's first-line share rose two to three percentage points in the second quarter.

Pfizer Inc. PFE competes through its Vyndaqel family, the therapy from which some Attruby patients have switched. Alnylam Pharmaceuticals, Inc. ALNY adds another ATTR-CM competitor through Amvuttra. Sustained first-line gains therefore matter as switching provides less incremental support.

BridgeBio’s Cash Position Supports More Launches

BridgeBio ended June with $720.2 million of cash, cash equivalents and marketable securities, down from $940.2 million at the end of the prior quarter. That figure excluded the $1 billion preferred equity financing that closed July 1 and lifted the cash balance to about $1.7 billion.

The added liquidity supports a period in which BridgeBio is preparing for three potential U.S. product launches over the next 12 months. BBP-418 has an FDA decision date of Nov. 27, 2026. Encaleret is under review for a May 8, 2027 decision, while infigratinib is targeted for a potential early- to mid-2027 launch if approved.

BBIO’s Ratings Reflect Growth With Execution Risk

The bottom line is that commercial momentum is clear, but earnings pressure remains. Attruby delivered the sales beat, while BridgeBio continues to absorb high development and commercialization costs and relies heavily on one marketed product.

BBIO currently carries a Zacks Rank #3 (Hold). Within the Style Score framework, a #3 Rank sits between the stronger #1 (Strong Buy) and #2 (Buy) categories and the weaker #4 (Sell) and #5 (Strong Sell) categories. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Growth Score of B is BBIO's strongest style signal, while the Momentum Score of D and Value Score of F are less favorable. Its VGM Score of D points to a mixed combined profile as BridgeBio works to sustain Attruby growth and execute on its launch pipeline.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research